Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12...25262728293031323334353637»
  • ||||||||||  A rare case of large cell neuroendocrine bronchial carcinoma with therapeutic response to ALK inhibitors (A6) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1141;    
    However, TKI sensitivity was generally lower and the disease course more aggressive, including atypical metastatic sites, than in case of ALK + lung adenocarcinoma, despite presence of the relatively favourable EML4-ALK V2 and wild-type TP53. Moreover, TKI efficacy did not correlate with detection of ALK mutations, since second-line alectinib showed the longest duration of response despite unremarkable ALK sequencing results, while later TKI lines did not confer clinical benefit, despite presence of putatively sensitive ALK mutations based on in vitro results.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Journal:  Inflammatory Myofibroblastic Tumor Driven by NovelFusion Responds to ALK Inhibition. (Pubmed Central) -  Sep 28, 2019   
    We review published reports of-driven IMTs that have received ALK inhibitor therapy and suggest characteristics that may be associated with favorable response to treatment. We also discuss the strengths and limitations of immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing in the diagnosis and management of IMTs.
  • ||||||||||  Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers (Level 3 - Ballroom AB) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_578;    
    Finally, the development of tyrosine kinase inhibitors beyond the first generation drug (lapatinib), such as neratinib and more recently tucatinib as well the development of antibody drugs conjugates such as T-DM1 all these therapeutic developments showed significant activity in case of resistance to trastuzumab and hopefully will help not only to control the disease but also to cure this group of breast cancer...Several drugs were developed in case of resistance such as sunitinib, regorafenib but with limited results...One of the mechanism of resistance to imatinib was the development of secondary mutations which should be targeted with more selective agents...Finally, one of the potential way to overcome the resistance (which appears during the evolution of the disease and in particular under the pressure of therapies) is to block the disease as early as possible of course at the micrometastatic state but also at what is considered today as residual disease following neoadjuvant systemic therapy or the molecular recurrence by using liquid biopsies before positive radiological recurrence. Innovative therapeutic strategies and study designs are needed here not only to understand the mechanisms behind residual/molecular recurrence disease but also to study/treat these settings.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
    Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients (Cordoba Auditorium (Hall 7)) -  Sep 11, 2019 - Abstract #ESMO2019ESMO_3317;    
    Therefore, therapeutic drug monitoring might be appropriate to individualize treatment and improve treatment outcomes. Legal entity responsible for the study: Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital.